National Technical Reports Library

The National Technical Information Service acquires, indexes, abstracts, and archives the largest collection of U.S. government-sponsored technical reports in existence. The NTRL offers online, free and open access to these authenticated government technical reports. Technical reports and documents in its repository may be available online for free either from the issuing federal agency, the U.S. Government Publishing Office’s Federal Digital System website, or through search engines.

Details

Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects.

AD1051151

Publication Date	2017
Personal Author	Conrad, K. P.
Page Count	11
Abstract	The overall objective is to provide proof-of-principle that recombinant human relaxin (rhRLX) administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesis/vasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated: reproducible implementation of uniform cranial lesions of ~1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ng/ml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice (~50 ).
Keywords	X-ray computed tomography Bone marrow Blood vessels Stem cells Bone fractures Osteogenesis Therapy Immunochemistry Cranial bone defects Healing Gfp+ chimeric mice Cranial defect closure Relaxin Angiogenesis Vasculogenesis Bone marrow-derived progenitor cells 3-d microcomputed tomography Immunohistochemistry Immunofluorescence Flow cytometry
Source Agency	Non Paid ADAS
NTIS Subject Category	57E - Clinical Medicine
Corporate Authors	Florida Univ., Gainesville.
Document Type	Technical Report
Title Note	Technical Report,01 Aug 2016,31 Aug 2017
NTIS Issue Number	201817

Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects.

Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects.
AD1051151

Publication Date	2017
Personal Author	Conrad, K. P.
Page Count	11
Abstract	The overall objective is to provide proof-of-principle that recombinant human relaxin (rhRLX) administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesis/vasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated: reproducible implementation of uniform cranial lesions of ~1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ng/ml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice (~50 ).
Keywords	X-ray computed tomography Bone marrow Blood vessels Stem cells Bone fractures Osteogenesis Therapy Immunochemistry Cranial bone defects Healing Gfp+ chimeric mice Cranial defect closure Relaxin Angiogenesis Vasculogenesis Bone marrow-derived progenitor cells 3-d microcomputed tomography Immunohistochemistry Immunofluorescence Flow cytometry
Source Agency	Non Paid ADAS
NTIS Subject Category	57E - Clinical Medicine
Corporate Authors	Florida Univ., Gainesville.
Document Type	Technical Report
Title Note	Technical Report,01 Aug 2016,31 Aug 2017
NTIS Issue Number	201817